Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Kineta (KA – Research Report), Gilead Sciences (GILD – Research Report) and Evotec AG (EVO – Research Report).
Kineta (KA)
In a report issued on January 18, Robert Burns from H.C. Wainwright reiterated a Buy rating on Kineta, with a price target of $8.00. The company’s shares closed last Monday at $2.66, close to its 52-week low of $1.78.
According to TipRanks.com, Burns has 0 stars on 0-5 stars ranking scale with an average return of
Kineta has an analyst consensus of Moderate Buy, with a price target consensus of $8.00.
See Insiders’ Hot Stocks on TipRanks >>
Gilead Sciences (GILD)
Bank of America Securities analyst Geoff Meacham maintained a Buy rating on Gilead Sciences yesterday and set a price target of $95.00. The company’s shares closed last Monday at $78.43.
According to TipRanks.com, Meacham is a 4-star analyst with an average return of
Gilead Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $90.59, representing a 12.5% upside. In a report issued on January 10, Jefferies also maintained a Buy rating on the stock with a $95.00 price target.
Evotec AG (EVO)
Bank of America Securities analyst Michael Ryskin maintained a Hold rating on Evotec AG yesterday and set a price target of $13.00. The company’s shares closed last Monday at $8.31, close to its 52-week low of $7.66.
According to TipRanks.com, Ryskin is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Evotec AG with a $17.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on KA:
- Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors
- Kineta provides update on ongoing Phase 1/2 VISTA-101 trial of KVA12123
- Kineta to Participate in the 13th Annual LifeSci Partners Corporate Access Event
- Kineta Publishes Preclinical Data Demonstrating the Potential of Anti-VISTA Antibody KVA12123 as an Immunomodulatory Therapy for Cancer
- Kineta publishes preclinical data on KVA12123
